Immunic Therapeutics is a Biotech company based in New York City. It has raised $400M in total funding. Latest round: Growth.
Immunic Therapeutics funding overview
Immunic Therapeutics is a Biotech company based in New York City. Immunic Therapeutics has raised $400M in total disclosed funding. That places its disclosed total in the $250M–$1B range. Its most recent disclosed round is a Growth announced in February 2026. The round record for Immunic Therapeutics runs through 2026; nothing later has been disclosed. Investors on record include LSP, Omega Funds, Fund+, LifeCare Partners, Bayern Kapital, High-Tech Gründerfonds and 1 others. 7 distinct backers are named across the disclosed rounds.
Frequently asked about Immunic Therapeutics funding
How much has Immunic Therapeutics raised?
Immunic Therapeutics has raised $400M in total disclosed funding across the rounds on record.
Who has invested in Immunic Therapeutics?
LSP, Omega Funds, Fund+, LifeCare Partners, Bayern Kapital, High-Tech Gründerfonds are named among the investors backing Immunic Therapeutics.
What was the latest Immunic Therapeutics funding round?
The most recent disclosed round is a Growth, announced in February 2026.
Where is Immunic Therapeutics based?
Immunic Therapeutics is based in New York City.
What sector does Immunic Therapeutics operate in?
Immunic Therapeutics is tracked under Biotech from New York City, with $400M in disclosed funding.
When did Immunic Therapeutics last raise?
The last disclosed Immunic Therapeutics round closed in February 2026 at Growth.
Totals shown for Immunic Therapeutics aggregate every disclosed round on file. To see how that compares, browse the Biotech companies in New York City and the investors behind them below.
